SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'ncav_real'
ARAV (Aravive) Net Current Asset Value
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Aravive's net current asset value per share for the quarter that ended in Sep. 2023 was $-0.02.
The historical rank and industry rank for Aravive's Net Current Asset Value or its related term are showing as below:
During the past 11 years, the highest Price-to-Net-Current-Asset-Value Ratio of Aravive was 12.00. The lowest was 0.82. And the median was 2.12.
ARAV's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.83 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Aravive Net Current Asset Value Historical Data
The historical data trend for Aravive's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Aravive Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Net Current Asset Value
4.31
3.68
2.55
1.77
0.11
Aravive Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Net Current Asset Value
0.35
0.11
-0.71
-0.39
-0.02
Competitive Comparison
For the Biotechnology subindustry, Aravive's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aravive Price-to-Net-Current-Asset-Value Distribution
For the Biotechnology industry and Healthcare sector, Aravive's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Aravive's Price-to-Net-Current-Asset-Value falls into.
Aravive Net Current Asset Value Calculation
Aravive's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aravive (NAS:ARAV) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Aravive Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of Aravive's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARAV has been successfully added to your 